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The bovine herpesvirus 1 (BHV-1) recombinants BHV-1/eGori and BHV-1/eGsyn were isolated after insertion
of expression cassettes which contained either a genomic RNA-derived cDNA fragment (BHV-1/eGori) or a
modified, chemically synthesized open reading frame (ORF) (BHV-1/eGsyn), which both encode the attachment
glycoprotein G of bovine respiratory syncytial virus (BRSV), a class II membrane glycoprotein. Northern blot
analyses and nuclear runoff transcription experiments indicated that transcripts encompassing the authentic
BRSV G ORF were unstable in the nucleus of BHV-1/eGori-infected cells. In contrast, high levels of BRSV G
RNA were detected in BHV-1/eGsyn-infected cells. Immunoblots showed that the BHV-1/eGsyn-expressed BRSV
G glycoprotein contains N- and O-linked carbohydrates and that it is incorporated into the membrane of
infected cells and into the envelope of BHV-1/eGsyn virions. The latter was also demonstrated by neutralization
of BHV-1/eGsyn infectivity by monoclonal antibodies or polyclonal anti-BRSV G antisera and complement. Our
results show that expression of the BRSV G glycoprotein by BHV-1 was dependent on the modification of the
BRSV G ORF and indicate that incorporation of class II membrane glycoproteins into BHV-1 virions does not
necessarily require BHV-1-specific signals. This raises the possibility of targeting heterologous polypeptides to
the viral envelope, which might enable the construction of BHV-1 recombinants with new biological properties
and the development of improved BHV-1-based live and inactivated vector vaccines.
Bovine herpesvirus 1 (BHV-1), a member of the subfamily
Alphaherpesvirinae with a double-stranded DNA genome of
approximately 136 kbp, causes infectious rhinotracheitis and
infectious pustular vulvovaginitis as the most common clinical
symptoms in cattle (27, 34, 39). Vaccination with attenuated
live viruses or inactivated virions is widely used to control the
disease and to reduce the concomitant financial losses. As with
other large DNA viruses, interest exists in the use of recom-
binant BHV-1 as an improved live vaccine against BHV-1
infection (1, 21, 42) or as a vector for bi- or multivalent vac-
cines against BHV-1 and additional bovine pathogens (17, 18).
To date, incorporation of heterologous genes into the genome
of BHV-1 has concentrated mainly on the expression of the
procaryotic lacZ gene to identify essential and nonessential
genes or as a reporter gene for analytical studies (3, 8, 12, 15,
20, 29, 37, 38, 45). Recently, BHV-1 has been used to express
biologically active bovine interleukins (21, 32) and glycopro-
teins of pseudorabiesvirus (19, 31). However, expression of
RNA virus-encoded proteins by BHV-1 has not been pub-
lished so far. Remarkably, expression of genes from cytoplasm-
replicating viruses by other herpesviruses of mammals has only
rarely been reported (5, 43).
Attempts to express the fusion glycoprotein F and the at-
tachment glycoprotein G of bovine respiratory syncytial virus
(BRSV), a pneumovirus of the family Paramyxoviridae which is
also prevalent worldwide and causes severe respiratory disease
in young calves similar to the disease caused by human respi-
ratory syncytial virus in children (4), were not successful (13,
33). Although the cDNA fragments encoding the respective
glycoproteins were flanked by transcription control elements
that are active in the genomic context of BHV-1 (21), no
BRSV-specific transcripts were detected in cells infected with
the BHV-1 recombinants (13) (see below). We therefore as-
sumed that RNAs containing the authentic BRSV sequences
were unstable in the nuclei of infected cells. To test this as-
sumption, the BHV-1 glycoprotein D (gD) codon usage pref-
erences (13, 40) were used to construct a modified open read-
ing frame (ORF) encoding the BRSV G glycoprotein by
chemically synthesized oligonucleotides.
In this report, we show that expression of the attachment
glycoprotein G of BRSV (BRSV G glycoprotein), a type II
membrane glycoprotein (36, 44), by BHV-1 was dependent on
the modification of the base composition of the ORF encoding
BRSV G glycoprotein, that virions produced by the recombi-
nant contained the BRSV G glycoprotein, and that the pres-
ence of this protein in the viral envelope does not significantly
interfere with the infectivity of BHV-1. Our findings suggest
that RNA viruses which replicate in the cytoplasm can contain
sequences or sequence elements that lead to instability of tran-
scripts within the nucleus.
* Corresponding author. Mailing address: Federal Research Centre for
Virus Diseases of Animals, D-17498 Insel Riems, Germany. Phone: 49-
38351-7272. Fax: 49-38351-7219. E-mail: Guenther.M.Keil.@rie.bfav.de.
3804
 o
n
 January 23, 2014 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
MATERIALS AND METHODS
Cell culture and viruses. BHV-1 strain Scho¨nbo¨ken (BHV-1/Scho¨) was ob-
tained from O. C. Straub (Federal Research Centre for Virus Diseases of Ani-
mals, Tu¨bingen, Germany) and propagated on Madin-Darby bovine kidney cell
clone Bu100 (MDBK-Bu100; kindly provided by W. Lawrence and L. Bello,
University of Pennsylvania, Philadelphia, Pa.). The cells were grown in Dulbec-
co’s minimum essential medium supplemented with 5% fetal calf serum (FCS),
100 U of penicillin per ml, 100 mg of streptomycin per ml, and 0.35 mg of
L-glutamine per ml. The gD-negative mutant BHV-1/80–221 was propagated on
the constitutively gD-expressing cell line BU-Dorf as described previously (38).
Construction and cloning of the BRSV Gsyn ORF. Oligonucleotides were
synthesized in a Biosearch 8700 instrument and purified by gel electrophoresis.
Complementary oligonucleotides were mixed in equal molar amounts in 10 mM
Tris-HCl (pH 7.5), boiled for 5 min, and slowly cooled to room temperature. All
the cloning procedures were performed by established methods (35). The fol-
lowing double-stranded DNA fragments were generated (restriction enzyme
cleavage sites used for cloning are shown in boldface type).
Fragment 1:
AAGCTTACAAGTATGAGCAACCACACGCACACGCACCACCTGAAGTTCAAGACGCTGAAG
TGCATTCGAATGTTCATACTCGTTGGTGTGCGTGTGCGTGGTGGACTTCAAGTTCTGCGACTTC
HindIII
CGCGCGTGGAAGGCTAGCAAGTACTTCATCGTCGGCCTGAGCTGCCTGTACAAGTTCAACCTGA
GCGCGCACCTTCCGATCGTTCATGAAGTAGCAGCCGGACTCGACGGACATGTTCAAGTTGGACT
AGAGCCTGGTCCAGACGGCGCTGAGCACGCTCGCGAG
TCTCGGACCAGGTCTGCCGCGACTCGTGCGAGCGCTCCTAG
NruI
Fragment 2:
CGATGATCACGCTGACGAGCCTGGTCATCACGGCGATCATCTACATCTCCGTGGGCAACGCG
GCTACTAGTGCGACTGCTCGGACCAGTAGTGCCGCTAGTAGATGTAGAGGCACCCGTTGCGC
AAGGCGAAGCCGACGTCG
TTCCGCTTCGGCTGCAGCCTAG
AatII
Fragment 3:
CGAAGCCGACGATCCAGCAGACGCAGCAGCCGCAGAACCACACGAGCCCGTTCTTCACGG
TGCAGCTTCGGCTGCTAGGTCGTCTGCGTCGTCGGCGTCTTGGTGTGCTCGGGCAAGAAGTGCC
AGCACAACTACAAGAGCACGCACACGAGCATCCAGAGCACGACCTTAAG
TCGTGTTGATGTTCTCGTGCGTGTGCTCGTAGGTCTCGTGCTGGAATTCCTAG
AflII
Fragment 4:
GCTTAAGCCAGCTGCTGAACATCGACACGACGCGCGGCATCACGTATGGCCACAGCACGA
ACGTCGAATTCGGTCGACGACTTGTAGCTGTGCTGCGCGCCGTAGTGCATACCGGTGTCGTGCT
AflII
ACGAGACGCAGAACCGCAAGATCAAAGGCCAGAGCACGCTGCCGGCGACGCGCAAGCCGCCGAT
TGCTCTGCGTCTTGGCGTTCTAGTTTCCGGTCTCGTGCGACGGCCGCTGCGCGTTCGGCGGCTA
CAACCCGAGCGGAT
GTTGGGCTCGCCTAGC
Fragment 5:
GAAGCTTATCGATACCGCCGGAGAACCACCAGGACCACAACAACTTCCAGACGCTGCC
ACGTCTTCGAATAGCTATGGCGGCCTCTTGGTGGTCCTGGTGTTGTTGAAGGTCTGCGACGG
ClaI
GTACGTCCCGTGCAGCACGTGCGAGG
CATGCAGGGCACGTCGTGCACGCTCCCATTG
Fragment 6:
GGTAACCTGGCGTGCCTGAGCCTGTGCCACATCGAGACGGAGCGCGCGCCGAGCCGGG
ACGTCCATTGGACCGCACGGACTCGGACACGGTGTAGCTCTGCCTCGCGCGCGGCTCGGCCC
BstEII
CCCCGACGATCACGCTGAAGAAGACGCCGAAGCCGAAGACGACGAAGAAGCCGACGAAGACG
GGGGCTGCTAGTGCGACTTCTTCTGCGGCTTCGGCTTCTGCTGCTTCTTCGGCTGCTTCTGC
ACGATCCACCACCGCA
TGCTAGGTGGTGGCGTGATC
Fragment 7:
GACTAGTCCGGAGACGAAGCTCCAGCCGAAGAACAACACGGCGACGCCGCAGCAAGGC
ACGTCTGATCAGGCCTCTGCTTCGAGGTCGGCTTCTTGTTGTGCCGCTGCGGCGTCGTTCCG
SpeI
ATCCTGAGCAGCACGGAGCACCACACGAACCAGAGCACGACGCAGATCTGAATTCA
TAGGACTCGTCGTGCCTCGTGGTGTGCTTGGTCTCGTGCTGCGTCTAGACTTAAGTTCGA
EcoRI
Fragment 1 was ligated into plasmid vector pUC18 after cleavage with AatII
and BamHI. In the resulting plasmid, pF1, the AatII cleavage site of pUC18 was
destroyed. Plasmid pF1 was cleaved with NruI and BamHI and received fragment
2 to produce pF2, into which fragment 3 was ligated after digestion with AatII
and BamHI to yield pF1-3. In parallel, pUC19 DNA was cleaved with HindIII
and PstI, fragment 7 was inserted, and the resulting plasmid, pF7, was cleaved
with PstI and SpeI and received fragment 6 to generate pF6. Plasmid pF6 was
incubated with PstI and BstEII, and fragment 5 was inserted. The plasmid
obtained, pF5, was treated with PstI and ClaI, and fragment 4 was integrated,
resulting in plasmid pF4. Plasmid pF4 was cleaved with XbaI, blunt ended with
Klenow polymerase, and recleaved with AflII. Into this DNA, the HindIII-AflII
fragment of pF1-3 was ligated after blunt ending of the HindIII site. The result-
ing plasmid, pBRSVGsyn, contained the reconstructed BRSV G ORF flanked by
EcoRI cleavage sites.
Other plasmid constructions. Plasmid pRSV02 (kindly provided by Paul Son-
dermejer, Intervet International, Boxmeer, The Netherlands), which contains a
cDNA fragment encoding the BRSV G glycoprotein, was cleaved with BglII. A
770-bp fragment, which encompasses codons 1 to 257 of the BRSV G ORF, was
ligated into plasmids pROMie and pROMe (21) cleaved with BglII followed by
insertion of a synthetic DNA fragment, obtained by hybridizing oligonucleotides
59-CATGCACACCTCCATATAA-39 and 59-CATGTTATATGGAGGTGTG-
39, as described above, into a single NcoI cleavage site to provide a stop codon.
The resulting plasmids, in which codon 259 was changed from CAA (encoding
glutamine) to ATG (encoding methionine), were named pROMieGori and
pROMeGori, respectively.
To construct recombination plasmid pROMeGsyn, plasmid pROMe was
cleaved with BglII, blunt ended with Klenow polymerase, and used for the
insertion of the synthetic G ORF, isolated from plasmid pBRSVGsyn after
cleavage with EcoRI and blunt ending with Klenow polymerase. For synthesis of
cRNA, the same fragment was integrated into the BglII-cleaved and blunt-ended
plasmid vector pSP73 (Promega, Heidelberg, Germany) to give plasmid pSPGsyn.
For in vitro transcription of the BRSV Gori ORF, a blunt-ended ClaI fragment
encompassing this ORF in plasmid pROMeGori was inserted into EcoRV-
cleaved pSP73. The resulting plasmid was designated pSPGori. The correctness
and orientation of the BRSV G ORFs were determined by dideoxy sequencing,
which showed that the 59 ends of the Gori and Gsyn ORFs were placed adjacent
to the T7 or SP6 promoter, respectively.
In vitro transcription and translation. Plasmids pSPGori and pSPGsyn were
linearized with BglII and HindIII, respectively, and cRNA was transcribed by T7
or SP6 RNA polymerase in the presence of the cap analog m7GpppG as specified
by the manufacturer (Boehringer GmbH, Mannheim, Germany). In vitro trans-
lation of the cRNAs was performed in the presence of 60 mCi of [35S]methionine
per reaction mixture as recommended by the supplier (Promega). Labeled pro-
teins were visualized by fluorography after sodium dodecyl sulfate-polyacrylam-
ide gel electrophoresis (SDS-PAGE) (10% polyacrylamide) as described previ-
ously (16).
RNA isolation, Northern blot hybridization, and nuclear runoff analysis.
Whole-cell RNA and cytoplasmic RNA was isolated as described previously (14,
35). Glyoxal-treated RNA (5 mg) was separated in 1% formaldehyde gels, trans-
ferred to nitrocellulose filters, and hybridized to 32P-labeled DNA by established
procedures (14, 35). Nuclear runoff transcription assays were performed by the
method of Greenberg and Ziff (11). Labeled RNA was hybridized to equimolar
(1.5 pmol) amounts of plasmid DNA dotted onto nitrocellulose filters with a dot
blot device (Schleicher & Schu¨ll, Dassel, Germany). Bound radioactivity was
visualized by autoradiography and quantitated by Cerenkov counting.
Antibodies and sera. BRSV G glycoprotein-specific monoclonal antibody
(MAb) 20 and MAb 57 and the polyclonal serum directed against BHV-1 gD are
described elsewhere (8, 9, 23). The anti-VacGsyn serum was raised in rabbits
infected with a recombinant vaccinia virus expressing the Gsyn ORF under
control of the p7.5 promoter. The rabbits were inoculated with 5 3 107 PFU and
bled 4 weeks after a booster immunization with 5 3 107 PFU given 1 week after
the initial infection. The BRSV-neutralizing titer was 1:80 in the presence of
complement. Polyclonal anti-BRSV hyperimmune serum 2106 was raised in
gnotobiotic calves after repeated inoculation with BRSV and had a BRSV-
neutralizing titer of 1:10,000 in the absence of complement (10).
Western blotting and immunoprecipitation. For Western blotting (immuno-
blotting), cells or purified virions were lysed in sample buffer. For analysis of
secreted proteins, infected cells were cultured with Dulbecco’s minimal essential
medium lacking FCS. Culture supernatants were clarified by ultracentrifugation
and, after addition of 3 volumes of ice-cold acetone, incubated for 15 min at
270°C. Precipitates were collected by centrifugation, air dried at room temper-
ature, and resuspended in sample buffer. The proteins were separated and
immunodetected as described previously (37). [35S]methionine-labeled proteins
were immunoprecipitated from purified virions as described by Fehler et al. (8).
The apparent molecular masses of proteins in SDS-polyacrylamide gels were
determined from standard curves with 14C-methylated protein molecular mass
standards (Amersham, Braunschweig, Germany) or prestained protein molecu-
lar mass standards (Gibco BRL, Eggenstein, Germany).
Deglycosylation reactions. Virions, purified as described previously (8), were
resuspended in 0.5% Nonidet P-40 in phosphate-buffered saline (PBS) and
incubated overnight at 37°C with 0.4 U of N-glycosidase F (Boehringer), 1 mU
of neuraminidase (Boehringer) or 1 mU of neuraminidase and 1.5 mU of O-
glycosidase (Boehringer). Immunoprecipitated proteins were incubated with the
respective enzymes under conditions recommended by the supplier.
Virus neutralization assays. Samples (approximately 200 PFU) of wild-type
and recombinant BHV-1 strains were incubated with serial dilutions of MAbs or
sera in a final volume of 100 ml of cell culture medium containing 20% FCS with
or without 5% normal rabbit serum as a source of complement and plated onto
MDBK-Bu100 cells after 1 h at 37°C. The cultures were overlaid with semisolid
medium 2 h later, and plaques were counted 2 to 3 days after infection. The
percent neutralization-resistant infectivity was calculated from the results with
controls incubated without antibody.
Infection of cells for indirect immunofluorescence. MDBK-Bu100 cell cultures
were infected with approximately 100 PFU and overlaid with semisolid medium.
After the development of plaques, the cultures were fixed with 3% paraformal-
dehyde in PBS and sequentially incubated with appropriate dilutions of MAbs or
sera and 5-(4,6-dichlorotriazin-2-yl)aminofluorescein (DTAF)-conjugated goat
anti-species immunoglobulin G (Dianova, Hamburg, Germany).
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RESULTS
Rationale for synthesis of a modified BRSV G glycoprotein
ORF. To express the BRSV G glycoprotein by recombinant
BHV-1, recombination plasmid pROMeGori, which contains a
cDNA fragment encompassing the BRSV G glycoprotein ORF
under control of the murine cytomegalovirus (MCMV) early 1
promoter (Fig. 1), was cotransfected with purified BHV-1/80–
221 DNA into MDBK cells and the progeny virus was serially
diluted and plated on MDBK cells. Since the ORF encoding
the essential gD is replaced by a lacZ expression cassette in
BHV-1/80–221 (8), only viruses which have acquired the gD
ORF by replacement of the lacZ cassette by the insert of the
recombination plasmid should be able to replicate on non-
complementing cells (21). Virus from plaques that did not
stain blue under a Bluo-Gal-containing agarose overlay were
again subjected to titer determination on MDBK cells, and
isolates which produced only “white” plaques were plaque
purified once more and characterized further (see Fig. 4).
Analysis of MDBK cells infected with the resulting recombi-
nant BHV-1/eGori gave no indication of BRSV G glycoprotein
expression by indirect immunofluorescence (see Fig. 7), and no
stable transcripts were detected within cytoplasmic RNA (data
not shown) or whole-cell RNA (see Fig. 5). BRSV G glyco-
protein expression was also not detected in transient-expres-
sion experiments with plasmid pROMieGori (Fig. 1) in which
the BRSV G glycoprotein ORF is under the control of the
MCMV immediate-early 1 enhancer/promoter element (data
not shown). In vitro translation of mRNA, transcribed in vitro
from pSPGori, resulted in synthesis of a polypeptide whose
apparent molecular mass of 31 kDa (Fig. 2, lane 2) was in good
agreement with the calculated size of 29 kDa (24). This result
indicated that mRNA from the BRSV Gori ORF contained
within pROMeGori has the potential to direct protein synthe-
sis, and we assumed that the failure to detect BRSV G glyco-
protein-specific gene products was due to instability of BRSV
G glycoprotein transcripts in the nuclei of BHV-1/eGori-in-
fected cells. Therefore, a modified ORF encoding the BRSV G
glycoprotein (Fig. 3) was chemically synthesized, isolated from
plasmid pBRSVGsyn, and inserted into pROMe and pSP73.
The resulting plasmids were named pROMeGsyn and pSPGsyn,
respectively, and RNA transcribed from pSPGsyn directed the
synthesis of a 31-kDa protein in a rabbit reticulocyte lysate
(Fig. 2, lane 3) that comigrated with the polypeptide synthe-
sized in vitro from the Gori ORF, supporting the conclusion
FIG. 1. Construction of BHV-1 recombinants. The schematic representation of the prototype orientation of the BHV-1 genome is shown above the HindIII
restriction fragment map of BHV-1 strain Scho¨nbo¨ken (7, 27). The wild-type HindIII L fragment is enlarged, and the location and direction of transcription of genes
encoding the putative protein kinase (PK) and glycoproteins G (gG), D (gD), I (gI), and E (gE) are indicated by arrows (15, 25, 40, 45). Relevant restriction enzyme
cleavage sites are marked. The respective HindIII fragment of the gD2 lacZ1 mutant BHV-1/80–221 is depicted below. The location and direction of transcription of
the lacZ cassette (dotted area, not drawn to scale) that replaces the gD ORF is indicated by an arrow. Underneath, a diagram of the integration fragment contained
in the recombination vectors is shown. The gD TATA and gD poly(A) segments indicate BHV-1 sequences representing the gD promoter and the gD polyadenylation
signal, respectively, which provide homologous regions for recombination. In this study, transcription of the BRSV Gori or Gsyn ORF (BRSVG ORF) was directed by
the MCMV ie1 enhancer-promoter element (6) in transient-expression experiments or by the MCMV e1 promoter (2) in recombinant BHV-1 infected cells.
Transcription of the BHV-1 gD ORF which is followed by the MCMV ie2 poly(A) signal (28) is under the control of the authentic gD promoter.
FIG. 2. Cell-free translation of cRNAs encompassing the BRSV Gori or Gsyn
ORF. 35S-labeled proteins translated in vitro from RNA transcribed in vitro from
plasmids pSPGori (lane 2) or pSPGsyn (lane 3) were size separated in SDS–10%
polyacrylamide gels and visualized by fluorography. In lane 1, proteins synthe-
sized from RNA transcribed from pSPGori antisense to the BRSV G glycopro-
tein ORF were separated. The apparent molecular mass of the translation
products, indicated in kilodaltons on the left, was calculated from the migration
of 14C-methylated protein molecular mass standards run on the same gel.
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that the 31-kDa protein represents the primary translation
product encoded by the BRSV G glycoprotein ORF.
Integration of the BRSV-Gsyn ORF into the genome of BHV-
1/80–221. Recombination plasmid pROMeGsyn was cotrans-
fected with purified BHV-1/80-221 DNA into MDBK cells,
and the recombinant virus, BHV-1/eGsyn, was isolated as de-
scribed above for BHV-1/eGori. To demonstrate integration of
the expression cassettes into the genomes of the respective
viruses, MDBK cells were infected with BHV-1/eGori, BHV-
1/eGsyn, and BHV-1/80–221, phenotypically complemented by
propagation on gD-expressing cells (8). Whole-cell DNA was
prepared 20 h postinfection (p.i.), cleaved with HindIII, trans-
ferred to nitrocellulose filters after size separation in 0.6%
agarose gels, and hybridized to Gsyn-, Gori-, and lacZ-specific
32P-labeled DNA fragments. The sizes of the fragments that
hybridized to the respective probes were as expected (data not
shown). We concluded that BHV-1/eGori and BHV-1/eGsyn
were generated by homologous recombination as envisaged.
Transcription of the BRSV Gori and BRSV Gsyn ORFs in
recombinant BHV-1-infected cells. To test for transcription
from the recombinant BRSV G genes, MDBK cells were in-
fected with BHV-1/eGsyn (Fig. 4, lanes 1, 3, 5, and 7) and
BHV-1/eGori (lanes 2, 4, 6, and 8). Cytoplasmic RNA was
isolated at 6 h p.i., size separated by agarose gel electrophore-
sis, and transferred to nitrocellulose filters. A 32P-labeled DNA
probe representing the BRSV Gsyn ORF detected an RNA of
1.3 kb after infection with BHV-1/eGsyn (lane 1) and, after
extended exposure, a transcript of 1.8 kb (lane 5) whose syn-
thesis is initiated approximately 500 bp upstream from the
MCMV e1 promoter (13). Even after a longer exposure, Gori
ORF-specific transcripts of the expected size were not detected
(lanes 2 and 6). The faint smear in lane 6 might indicate the
presence of fragmented Gori RNA. Hybridization of the filters
with 32P-labeled DNA encompassing the BHV-1 gD ORF
showed that comparable amounts of gD mRNA were detected
in BHV-1/eGsyn-infected cells (lanes 3 and 7) and BHV-1/
eGori-infected cells (lanes 4 and 8), demonstrating that the
FIG. 3. Comparison of the nucleotide sequences of the BRSV G glycoprotein cDNA ORF (upper sequence) and the Gsyn ORF (lower sequence). Exchanged
nucleotides are in boldface type, and the deduced BRSV G glycoprotein amino acid sequence is shown in the single-letter code.
FIG. 4. Identification of transcripts encompassing the Gsyn ORF. Whole-cell
RNA from cells infected with BHV-1/eGsyn (lanes 1, 3, 5, and 7) and BHV-1/
eGori (lanes 2, 4, 6, and 8) was prepared at 6 h p.i., and 5-mg samples were
transferred to nitrocellulose after 1% agarose gel electrophoresis. The filters
were hybridized to 32P-labeled DNA from the BRSV-Gsyn ORF (lanes 1 and 5),
the BRSV-Gori ORF (lanes 2 and 6), and the BHV-1 gD ORF (lanes 3, 4, 7, and
8). Bound radioactivity was visualized by autoradiography. Lanes 5 to 8 are
longer exposures of lanes 1 to 4. Transcript sizes are indicated in kilobases.
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absence of stable transcripts from the BRSV Gori ORF was not
due to degradation of the RNA from BHV-1/eGori-infected
cells. Substantially the same results were obtained with RNAs
isolated 16 h after infection with BHV-1/eGsyn and BHV-1/
eGori in the absence or presence of phosphonoacetic acid (data
not shown).
To support the assumption that transcripts from the BRSV
Gori ORF are unstable in BHV-1/eGori-infected cells, elonga-
tion of initiated transcripts in BHV-1/eGori- and BHV-1/eGsyn-
infected MDBK cells was analyzed by nuclear runoff transcrip-
tion assays. 32P-labeled RNA, synthesized in nuclei isolated at
6 h p.i., was hybridized to DNA from the plasmid vector pSP73
or from plasmids pSPGori, pSPGsyn, or pSPgD dotted onto
nitrocellulose membranes. Elongation of RNA from both
BRSV G ORFs was detected (data not shown). The ratio of
bound radioactivity between the respective BRSV G ORFs
and the corresponding BHV-1 gD ORFs was 1.7 with RNA
from BHV-1/eGori-infected cells and 2.1 with RNA from
BHV-1/eGsyn-infected cells, demonstrating that the Gori ORF
was transcribed in BHV-1/eGori-infected cells. These results
are in accordance with the conclusion that BHV-1-expressed
BRSV Gori RNAs are unstable in the nuclei of infected cells.
Identification and characterization of BHV-1-expressed
BRSV G glycoprotein. To test for the expression of the BRSV
G glycoprotein in BHV-1/eGsyn-infected cells, BRSV G glyco-
protein-specific MAb 20 and a polyclonal antiserum (anti-
VacGsyn), raised in rabbits after infection with Gsyn-expressing
recombinant vaccinia virus, were used to stain wild-type
BHV-1 strain Scho¨nbo¨ken (BHV-1/Scho¨)-, BHV-1/eGsyn-, or
BHV-1/eGori-induced plaques by indirect immunofluores-
cence. The cultures were fixed 2 days after infection and incu-
bated with the BHV-1 gD-specific MAb 21/3/3, MAb 20, or the
anti-VacGsyn serum. Antibodies bound on the cell surface were
visualized by using DTAF-conjugated anti-species immuno-
globulin G and fluorescence microscopy. As shown in Fig. 5,
MAb 20 and the anti-VacGsyn serum bound only to cells in
plaques generated by BHV-1/eGsyn whereas MAb 21/3/3 re-
acted with gD on the surface of cells infected with BHV-1/
Scho¨, BHV-1/eGsyn, and BHV-1/eGori. The conclusion that the
BRSV Gsyn ORF-encoding protein is expressed on the surface
of BHV-1/eGsyn-infected cells was also demonstrated by flow
cytometry with living cells and the same antibodies as above
(data not shown).
To further characterize the BRSV Gsyn ORF-encoded gene
product, proteins from infected cells (Fig. 6, lanes 1 to 4),
purified virions (lanes 5 to 7), and the cell culture medium
from BHV-1/eGsyn-infected cells (lane 8) were analyzed by
immunoblotting because MAb 20 and the anti-VacGsyn serum
did not work for immunoprecipitation. MAb 20 did not spe-
cifically bind to proteins from cells infected with BHV-1/Scho¨
(Fig. 6, lane 1) and BHV-1/eGori (lane 2) or to proteins from
purified BHV-1/Scho¨ and BHV-1/eGori virions (lanes 5 and 6)
but reacted strongly with proteins with apparent molecular
masses of 38 and 43 kDa from BHV-1/eGsyn-infected cells
(lane 3). In addition, several weaker-staining bands ranging in
size from 70 to about 100 kDa were detected. To elucidate
FIG. 5. BHV-1-encoded BRSV G glycoprotein is expressed on the cell surface. MDBK cell cultures were infected with approximately 100 PFU of BHV-1/Scho¨,
BHV-1/eGsyn, and BHV-1/eGori, fixed after the development of plaques, and used for indirect immunofluorescence with BHV-1 gD-specific MAb 21/3/3, BRSV G
glycoprotein-specific MAb 20, and the anti-VacGsyn serum. Bound antibodies were visualized by staining with DTAF-conjugated goat anti-species immunoglobulin G.
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possible precursor-product relationships among the MAb 20-
reactive polypeptides, BHV-1/eGsyn-infected cells were incu-
bated for 2 h with cycloheximide (final concentration, 100 mg
per ml) before lysis to inhibit de novo protein synthesis. This
treatment resulted in a considerable decrease in the signal at
38 kDa and a slight reduction in the band intensity of the signal
at 43 kDa, whereas the bands corresponding to larger proteins
increased in size and abundance (Fig. 6, lane 4). Prolongation
of the cycloheximide incubation time did not significantly alter
this pattern but resulted in a decrease in the intensities of all
bands (data not shown). Among proteins from purified virus
particles, MAb 20 bound only to polypeptides from BHV-1/
eGsyn virions which migrated as a diffuse band with an appar-
ent molecular mass between 70 and 120 kDa (lane 7). No MAb
20-reactive proteins were detected in the medium of BHV-1/
eGsyn-infected cells (lane 8). Identical results were obtained
with the anti-VacGsyn serum and BRSV G glycoprotein-spe-
cific MAb 57 (9). The latter immunoprecipitated the large
molecules but not the 38- and 43-kDa proteins from cells
infected with BHV-1/eGsyn in the presence of [
35S]methionine
and [35S]cysteine. From these results, we conclude that the 38-
and 43-kDa proteins represent BRSV G glycoprotein precur-
sor molecules which are subsequently modified to the large
form, which is also associated with BHV-1/eGsyn virions.
The carbohydrate composition of virus particle-associated
BRSV G glycoprotein was analyzed by incubation of purified
BHV-1/eGsyn virions with glycosidase F, neuraminidase, and
neuraminidase together with O-glycosidase followed by immu-
noblotting after SDS-PAGE with MAb 20 (Fig. 7a) or a poly-
clonal rabbit serum raised against purified BHV-1 gD (Fig. 7b)
to monitor the reactions. According to the enzymes used, the
electrophoretic mobilities of virion-associated gD increased as
expected (41), and no differences were detected in comparison
to the reaction products of immunoprecipitated virion gD (Fig.
7b and c), indicating the presence of sufficient enzymatic ac-
tivity for complete deglycosylation within the respective
probes. The BRSV G glycoprotein molecules appeared unaf-
fected after incubation with neuraminidase (Fig. 7a, lane 2)
and exhibited an increased electrophoretic mobility following
digestion with neuraminidase and O-glycosidase (lane 3) or
N-glycosidase F (lane 4), which demonstrates the presence of
O- and N-linked carbohydrates in the virion-associated BRSV
G glycoprotein. However, digestion products obtained after
incubation of the virion proteins with neuraminidase and O-
glycosidase migrated slower and were more diffuse, as ex-
pected for the only N-glycosylated form. Whether this discrep-
ancy is due to additional modifications, the presence of
O-glycosidase-resistant O-linked carbohydrates (22), or incom-
plete removal of O-linked glycans due to specifics of the BRSV
G glycoprotein has to be analyzed.
Virus neutralization assays. The immunoblot analysis in Fig.
6 indicated that BHV-1/eGsyn virus particles contain the BRSV
G glycoprotein and therefore should be susceptible to inacti-
vation by BRSV G glycoprotein-specific antibodies. BHV-1/
eGori and BHV-1/eGsyn virions were tested for complement-
dependent and -independent neutralization by MAb 57, the
anti-VacGsyn serum, and the anti-BRSV serum 2106 (9). With
complement, MAb 57, which had no effect on the infectivity of
BHV-1/eGori (data not shown), reduced the number of BHV-
1/eGsyn-induced plaques to 52% at a final dilution of 1:25. The
anti-VacGsyn serum specifically neutralized BHV-1/eGsyn in
the presence of complement to 50% neutralization at a dilu-
tion of about 1:1,000 (Fig. 8). No activity was detectable with-
out complement (data not shown). The BHV-1/eGsyn-neutral-
izing activity of anti-BRSV serum 2106 was weak in the
absence of complement and more pronounced after the addi-
tion of complement. Both polyclonal sera had no significant
effect on the infectivity of BHV-1/eGori (Fig. 8) and BHV-1/
Scho¨ (data not shown).
DISCUSSION
Analysis of the expression from the authentic BRSV G gly-
coprotein ORF after infection of cells with BHV-1/eGori indi-
cated that the transcripts are unstable in the nucleus. We
assumed that this was due to the nucleotide sequence of the
RNA, which might contain signals that do not interfere with
the stability of the RNA in the cytoplasm of cells infected with
BRSV or recombinant vaccinia virus expressing the BRSV G
glycoprotein (24) but result in degradation of the transcripts in
the nucleus. Therefore, the complete BRSV G glycoprotein
ORF was reconstructed by using synthetic oligonucleotides.
The codon usage of the modified ORF was adjusted to that of
BHV-1 gD, resulting in an increase of the G1C content from
42 to 62%, and the introduction of putative splice donor signals
(30) was avoided. The synthetic ORF was inserted into the
genome of BHV-1 under the control of the MCMV e1 pro-
moter (2, 21), and analysis of the gene products in BHV-1/
eGsyn-infected cells demonstrated transcription of mRNA,
FIG. 6. Identification of the BHV-1/eGsyn-expressed BRSV G glycoprotein.
MDBK cells were infected with BHV-1/Scho¨ (lanes 1 and 5), BHV-1/eGori (lanes
2 and 6), and BHV-1/eGsyn (lanes 3, 4, 7, and 8). Proteins from infected cells,
harvested at 10 h p.i. (lanes 1 to 4), from purified virions (lanes 5 to 7), and from
cell culture medium (lane 8), were analyzed by immunoblotting with BRSV G
glycoprotein-specific MAb 20. Proteins shown in lane 4 were from cells incubated
with cycloheximide (100 mg/ml) for 2 h before lysis. Apparent molecular masses
are indicated in kilodaltons.
FIG. 7. Evidence that BHV-1-expressed G glycoprotein contains N- and O-
linked sugars. (a and b) Purified BHV-1/eGsyn virions were resuspended in PBS
plus 0.5% NP-40 and digested overnight at 37°C with neuraminidase (lanes 2),
neuraminidase and O-glycosidase (lanes 3), N-glycosidase F (lanes 4), and with-
out enzyme (lanes 1). Digestion products were analyzed by immunoblotting with
G glycoprotein-specific MAb 20 (a) or a polyclonal, BHV-1 gD-specific rabbit
antiserum (b). (c) Purified, [35S]methionine-labeled BHV-1/Scho¨ virions were
lysed and incubated with gD-specific MAb 21/3/3. Immunoprecipitated proteins
were incubated as described above, separated on SDS–10% polyacrylamide gels,
and visualized by fluorography. The apparent molecular masses, indicated in
kilodaltons on the left, were calculated from the migration of prestained (a and
b) or 14C-methylated protein molecular mass standards (c) run on the respective
gel.
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which was translated into proteins recognized by BRSV G
glycoprotein-specific MAb 20 and the anti-VacGsyn serum. Al-
though we did not attempt to delineate sequence motifs lead-
ing to instability of the Gori transcripts in the nucleus, our
results strongly suggest their existence, which might also ex-
plain the failure to express the authentic ORF encoding BRSV
fusion protein F by BHV-1 (13). Introduction of a series of
single restriction enzyme cleavage sites into the Gsyn ORF will
be helpful in identifying sequence elements that prevent the
generation of mRNA from the genomic BRSV G glycoprotein
ORF, which may be beneficial for the development of systems
for the expression of RNA virus genes in the nuclei of mam-
malian cells.
The BRSV G glycoprotein is a type II membrane glycopro-
tein with a 37-amino-acid N-terminal cytoplasmic domain fol-
lowed by 29 hydrophobic amino acids representing the trans-
membrane region. The remaining 191 amino acids are mainly
hydrophilic and constitute the extracellular domain (24).
Among BHV-1/eGsyn-infected cell proteins, MAb 20, MAb 57,
and the anti-VacGsyn serum detected proteins with apparent
molecular masses of 38, 43, and 70 to 120 kDa. Inhibition of de
novo protein synthesis by cycloheximide resulted in a decrease
of the signals generated by the 38- and 43-kDa proteins and a
concomitant increase in intensity and size of the large-protein
band. Although the exact precursor-product relationship
awaits clarification, we assume that the 38- and 43-kDa pro-
teins represent precursor molecules of the mature BRSV G
glycoprotein. This assumption is in accordance with results
reported by Lerch et al. (24), who demonstrated that in cells
infected with a BRSV G glycoprotein-expressing recombinant
vaccinia virus, two proteins which migrated with an apparent
molecular mass of 43 kDa and as a broad band between 68 and
97 kDa specifically reacted with an anti-BRSV serum in im-
munoblots. They further provided evidence that the 43-kDa
form represents a precursor containing only N-linked carbo-
hydrates whereas the 68- to 97-kDa molecules constitute the
mature N- and O-glycosylated BRSV G glycoprotein.
Expression of the BRSV G glycoprotein in BHV-1/eGsyn-
infected cells was analyzed only by immunoblotting because
the BRSV G glycoprotein-specific MAb 20 and the anti-
VacGsyn serum did not work for immunoprecipitation and
MAb 57 precipitated only the mature glycoprotein after syn-
thesis in the presence of [35S]methionine and [35S]cysteine (not
shown). The observation that antibodies against the BRSV G
glycoprotein bind in immunoblots but fail to immunoprecipi-
tate the antigen is, although surprising, not without precedent
and has also been reported by Lerch et al. (24). The reason for
this apparent paradox, however, remains unclear.
Immunofluorescence and flow cytometry (data not shown)
with MAb 20 and the anti-VacGsyn serum demonstrated that
BHV-1/eGsyn-infected cells expressed the BRSV G glycopro-
tein on the cell surface, and we conclude that it is tightly
anchored in the cell membrane since no secreted molecules
were found in the medium from BHV-1/eGsyn-infected cul-
tures. Thus, our results indicate Golgi processing and post-
Golgi transport of the BHV-1/eGsyn-encoded BRSV G glyco-
protein to the cell surface, comparable to the situation in
BRSV- or recombinant vaccinia virus-infected cells (24).
Since alphaherpesviruses probably do not encode type II
glycoproteins, we investigated whether the BRSV G glycopro-
tein that presumably lacks any herpesvirus-specific targeting
signals is incorporated into BHV-1 particles. Western blot
analysis with MAb 20 revealed incorporation of the BRSV G
glycoprotein into purified virus particles, and this was con-
firmed by the susceptibility of BHV-1/eGsyn virions to neutral-
ization by the anti-VacGsyn serum, the anti-BRSV immune
serum, and MAb 57 in the presence of complement. That these
antibodies did not neutralize in the absence of complement
was not too surprising, since it is unlikely that the BRSV G
glycoprotein exhibits a biological function for the infectivity of
BHV-1. In addition, flow cytometry demonstrated that MAb
20 and the anti-VacGsyn serum bound to living cells infected
with purified BHV-1/eGsyn virions in the presence of cyclohex-
imide to prevent de novo protein synthesis (13). This further
supports the conclusion that the orientation of the BRSV G
glycoprotein within the viral envelope is correct.
To our knowledge, this is the first description of a class II
membrane glycoprotein becoming incorporated into alphaher-
pesvirus virions. The presence of the BRSV G glycoprotein in
the given background of BHV-1/eGsyn exerted only a slight
influence on the entry of virions into target cells in comparison
to the situation for wild-type BHV-1 (data not shown). Al-
though no repaired viruses were included in this study, we
believe that it is reasonable to assume that BRSV G glycopro-
tein does not significantly interfere with the envelope struc-
tures required for the initial steps of the BHV-1 infection.
This study has practical implications for herpesvirus-based
vector vaccine development: (i) it indicates that modification
of RNA virus genes may be required for efficient expression,
and (ii) it raises the possibility of targeting foreign antigens as
class II membrane (glyco)proteins into the envelope of her-
pesvirus virions, which might be important when booster vac-
cinations with live recombinant viruses are inefficient due to
FIG. 8. BHV-1/eGsyn virions are susceptible to neutralization by antibodies
against the BRSV G glycoprotein. Approximately 200 PFU of BHV-1/eGori was
incubated with 20% fetal calf serum plus complement or serial dilutions of
anti-VacGsyn with complement (open squares) or the anti-BRSV hyperimmune
serum with complement (open circles), and about 160 PFU of BHV-1/eGsyn was
incubated with 20% FCS and complement or with serial dilutions of anti-
VacGsyn and complement (solid squares), MAb 57 with complement (stars),
anti-BRSV serum 2106 without complement (solid triangles, no complement
added to the FCS control), or anti-BRSV serum 2106 with complement (solid
circles). After 60 min at 37°C, the virions were plated on MDBK cells and the
cultures were overlaid with semisolid medium. Plaques were counted 3 days
later. The plaque count of each FCS control was defined as 100% neutralization-
resistant infectivity. Serum dilutions are indicated.
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existing immunity to the vector, a situation observed with re-
combinant vaccinia viruses (13, 26).
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